γδ T Cell Activation and Expansion ServicesOnline Inquiry
γδ T cells are promising candidates for developing anti-cancer immunotherapy. However, the lack of suitable expansion methods has hindered the wide application of γδ T cells in cellular immunotherapy. Creative Biolabs has organized a staff of excellent experts who have focused on the research of γδ T cell for many years. We provide optimal solutions for γδ T cell activation and expansion to support the development of γδ T cell-based immunotherapies.
Brief Introduction to γδ T Cell Activation and Expansion
γδ T cells have been regarded as promising candidates for developing γδ T cell based anti-tumor immunotherapy due to their unique anti-tumor activities. During the development of γδ T cell based immunotherapy, it is very important to achieve enough numbers of γδ T cell. In general, there have two strategies for γδ T cell expansion: ex vivo and in vivo. The first method is to expand γδ T cells isolated from peripheral blood mononuclear cells (PBMCs) ex vivo using synthetic phosphoantigen (pAg) or bisphosphonates (BP) such as zoledronic acid. These ex vivo expanded γδ T cells have been applied in clinical trials and shown promising anti-tumor effects. The second method is to stimulate and expand γδ T cells in vivo by systemic administration of pAg or nitrogenous-BP (N-BP).
Creative Biolabs is a world-leading service provider who is devoted to offering the best γδ T cell development services for global clients, including γδ T cell isolation, activation and expansion, characterization, production, cytotoxicity test, and migration assay. Especially, our scientists are very skilled in the research of γδ T cell activation and expansion and can offer a great diversity of in vitro or in vivo solutions, including a customized solution for γδ T cell activation and expansion.
Vγ9Vδ2 T cells are the most abundant subset of circulating γδ T cells that has several features such as MHC-independent recognition of tumor cells and potent anti-tumor potential. Several studies have reported Vγ9Vδ2 cells can be activated and expanded in vitro and in vivo, thus make it possible to developing Vγ9Vδ2 cell-based immunotherapy. We offer top-quality services for activation and expansion of Vγ9Vδ2 T cells, accelerating the development of Vγ9Vδ2 cell-based immunotherapy.
Non-Vγ9Vδ2 T cells have been also revealed to exert a potent anti-tumor effect. Vδ1 γδ T cells (1-3% of lymphocytes) expanded from peripheral blood exhibited potent anti-tumor activity against multiple types of cancer, such as chronic lymphoid leukemia, multiple myeloma, breast cancer, and colorectal cancer. These non-Vγ9Vδ2 T cells have also attracted considerable attention for developing cancer immunotherapeutic approaches. We also offer multiple strategies for activation and expansion of non-Vγ9Vδ2 T cells (such as Vδ1 γδ T cells) to advance the development of non-Vγ9Vδ2 cell-based immunotherapy.
If you are interested in our γδ T cell activation and expansion services, please contact us for more details.